Introducción
The use of GLP-1 receptor agonists has been associated with improved remission rates in patients suffering from ulcerative colitis, according to findings from a retrospective cohort study involving 300 patients.
Among those with ulcerative colitis, the administration of liraglutide (Victoza, Saxenda) or semaglutide (Ozempic, Wegovy) for metabolic conditions was linked to significantly higher remission rates at 4 weeks (34.7% vs 15.3%, P=0.001), 8 weeks (54.7% vs 18%, P<0.001), and 12 weeks (66.7% vs 25.3%, P<0.001).
Análisis Detallado
The study found that after adjusting for age, sex, baseline partial Mayo score, obesity, diabetes status, and category of concomitant biologic therapy, the use of GLP-1 drugs was strongly linked to symptomatic remission (adjusted OR 5.90, 95% CI 3.52-9.86, P<0.001).
When examining the types of GLP-1 medications, there was a modest advantage noted for semaglutide over liraglutide, with remission rates of 72.5% compared to 60% at 12 weeks, respectively (OR 1.77, 95% CI 1.02-3.25, P=0.04).
Importantly, clinical improvement was noted before significant weight loss, suggesting a possible weight-independent anti-inflammatory mechanism.
Implicaciones Clínicas
These real-world findings advocate for a potential supplementary role of GLP-1 receptor agonists in managing ulcerative colitis, albeit prospective studies, including randomized controlled trials, are necessary for confirmation.
Prior research has suggested that GLP-1 agonists may provide benefits in inflammatory bowel diseases (IBD), extending beyond their metabolic indications. For example, a recent study indicated that these drugs were associated with lower corticosteroid dependence and fewer hospitalizations in adults with Crohn’s disease.
Mecanismos Celulares
Preclinical studies indicate that GLP-1 signaling can lower pro-inflammatory cytokine levels, enhance epithelial barrier functions, and attenuate colonic inflammation in experimental IBD models. Furthermore, GLP-1 receptor activation may assist in mucosal healing through immune modulation and improved intestinal permeability.
Detalles del Estudio
This particular study utilized electronic health records from the West Virginia University health system between 2022 and 2024, focusing on 300 patients with ulcerative colitis — 150 who received liraglutide or semaglutide and 150 in a control cohort who did not receive these medications.
Both groups had mean ages of similar range (46 vs 47 years), and a significant majority were women, with about 80% classified as overweight or obese (BMI ≥30). Type 2 diabetes was present in 35% of users and 34% of non-users.
The primary outcome evaluated was symptomatic remission at 12 weeks, defined as a partial Mayo score ≤2, indicating minimal to no symptoms.
Average partial Mayo scores showed significant improvement from 5.8 to 2.1 in the GLP-1 receptor agonist group, compared to an improvement from 5.7 to 4.6 in controls (P<0.001).
Exploratory analysis showed that 58% of the GLP-1 group achieved endoscopic remission compared to 38% in the control group.
Moreover, in the GLP-1 group, mean weight loss was around 8.2% at 12 weeks; however, a multivariable analysis indicated that this weight loss was not independently linked to remission.
Common gastrointestinal side effects were noted, such as transient nausea in 30% of patients and occasional vomiting in 10%, but no significant adverse events related to IBD were reported.
Consideraciones Finales
The authors caution that the limitations of a retrospective study may influence the results, as residual confounding factors cannot be fully accounted for.
Disclaimer: This information is intended for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Fuente: https://www.medpagetoday.com/gastroenterology/inflammatoryboweldisease/122775
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
